Trellis Bioscience, Inc. Spin-Out Crovela Raises $7 Million Series A

5/25/2006 – Trellis Bioscience Inc., a biopharmaceutical company, said that it has launched Crovela BioPharm Inc. around fibrosis technology in-licensed from Rice University. With its launch, Crovela has raised a $7 million Series A round.